YMAB

Y-mAbs Therapeutics Inc.

Price

return (12m)

p/e

-20.98

p/bv

4.43

DIVIDEND YIELD

0.00%

YMAB price

Y-mAbs Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment YMAB

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals YMAB

Valuation

P/E

-20.98

Sector -3.50

Industry -3.50

P/BV

4.43

Sector 2.02

Industry 2.02

P/Revenue (PSR)

4.48

Sector 2.01

Industry 2.01

EV/EBITDA

-58.59

Sector -214.99

Industry -214.99

EV/EBIT

-58.06

Sector -47.59

Industry -47.59

P/EBITDA

-16.56

Sector -21.41

Industry -21.41

P/EBIT

-16.36

Sector -28.65

Industry -28.65

P/Total Assets

3.31

Sector 1.19

Industry 1.19

P/Net Current Assets

6.24

Sector -11.97

Industry -11.97

P/Working Capital

5.63

Sector -167.95

Industry -167.95

EPS

-0.41

Sector -1.81

Industry -1.81

BVPS

1.94

Sector 2.06

Industry 2.06

Efficiency

Gross Margin

81.29%

Sector 41.30%

Industry 41.30%

EBITDA Margin

-28.43%

Sector -17,117.21%

Industry -17,117.21%

EBIT Margin

-28.69%

Sector -4,185,659.35%

Industry -4,185,659.35%

Operating Margin

-27.39%

Sector -35.21%

Industry -35.21%

Net Profit Margins

-21.37%

Sector -35.91%

Industry -35.91%

Asset Turnover

0.17

Sector 0.02

Industry 0.02

Profitability

ROE

-21.11%

Sector -56.04%

Industry -56.04%

ROA

-15.76%

Sector -60.31%

Industry -60.31%

ROIC

-61.43%

Sector -2,335.95%

Industry -2,335.95%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

4.00

Sector 2.89

Industry 2.89

Net Debt / EBITDA

11.22

Sector -14,066,680.10

Industry -14,066,680.10

Net Debt / EBIT

11.12

Sector -8.06

Industry -8.06

Net Debt / Equity

-0.71

Sector -33,024.69

Industry -33,024.69

Gross Debt / Equity

0.00

Sector -0.85

Industry -0.85

Equity/Assets

0.75

Sector 0.46

Industry 0.46

Liabilities/Assets

0.25

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

17.57%

Sector -

Industry -

5Y Earnings CAGR

-30.94%

Sector -

Industry -

Fundamentals YMAB

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
YMAB Y-mAbs Therapeutics Inc.	$0.00	-100.00%	0.00%	-20.98	4.43	-21.11%	-21.37%
JNJ Johnson & Johnson	$269.33	55.44%	1.96%	30.82	7.63	24.76%	21.48%
PFE Pfizer Inc.	$27.49	22.33%	6.26%	35.85	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$263.93	23.34%	2.59%	73.99	-78.76	-106.44%	9.81%
NVO Novo Nordisk A/S	$43.19	-26.70%	4.29%	10.56	5.61	53.11%	35.32%
MRK Merck & Co. Inc.	$146.11	87.14%	2.31%	113.21	8.55	7.55%	4.76%
AZN AstraZeneca PLC	$166.35	9.78%	1.94%	19.88	5.12	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$62.71	43.77%	4.04%	13.67	5.68	41.55%	18.85%
ZTS Zoetis Inc.	$72.66	-49.60%	2.88%	11.47	9.64	84.02%	27.77%
AMGN Amgen Inc.	$383.04	43.28%	2.60%	23.66	17.70	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$784.44	31.54%	0.47%	18.63	2.54	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$111.35	46.87%	0.00%	31.57	90.97	288.13%	24.86%
MCK McKesson Corporation	$874.67	27.00%	0.38%	19.57	-26.84	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$506.08	30.72%	0.00%	29.15	6.34	21.76%	35.00%
CAH Cardinal Health Inc.	$224.45	52.89%	0.91%	30.53	-19.32	-63.29%	0.68%
ARGX argenx SE	$994.44	35.42%	0.00%	2.24	2.63	117.11%	44.68%
HRMY Harmony Biosciences Holdings Inc.	$42.23	31.71%	0.00%	13.50	2.45	18.14%	18.88%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

YMAB Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Y-mAbs Therapeutics

Y-mAbs Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

11 years

Founded: 2015

2018

Time since IPO - 8 years

104

Employees

Y-mAbs Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $387.45 million, with shareholders equity totaling $87.49 million.

The company employs approximately 104 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Y-mAbs Therapeutics Inc. reported $86.44 million in revenue, generating net income of $-18.47 million.

Key financial metrics include a P/E ratio of -20.98, a price-to-book (P/B) ratio of 4.43, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker YMAB.

Market cap

$387.45 million

Net worth

$87.49 million

$87,490,000.00

Assets

$117.21 million

$117,210,000.00

Total Shares Outstanding

45.00 million

45,000,000

Average Daily Trading Volume

$1.07 million

$1,065,291.50

Sector

Health Care

Industry

Biotechnology

YMAB

YMAB revenue and profits

Financial Results YMAB

DRAG THE FRAME TO SEE MORE DATA

YMAB cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$874.67 25,76% (12M)

P/E

19.57

0.38%

ROE

-137.16%

P/BV

-26.84

CAH - Cardinal Health

$224.45 51,61% (12M)

P/E

30.53

0.91%

ROE

-63.29%

P/BV

-19.32

JNJ - Johnson & Johnson

$269.33 56,33% (12M)

P/E

30.82

1.96%

ROE

24.76%

P/BV

7.63

ABBV - AbbVie

$263.93 22,42% (12M)

P/E

73.99

2.59%

ROE

-106.44%

P/BV

-78.76

MRK - Merck & Co.

$146.11 85,19% (12M)

P/E

113.21

2.31%

ROE

7.55%

P/BV

8.55

AZN - AstraZeneca

$166.35 9,17% (12M)

P/E

19.88

1.94%

ROE

25.77%

P/BV

5.12

PFE - Pfizer

$27.49 22,43% (12M)

P/E

35.85

6.26%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$874.67 25,76% (12 M)

P/L

19.57

0.38%

ROE

-137.16%

P/VP

-26.84

CAH - Cardinal Health

$224.45 51,61% (12 M)

P/L

30.53

0.91%

ROE

-63.29%

P/VP

-19.32

JNJ - Johnson & Johnson

$269.33 56,33% (12 M)

P/L

30.82

1.96%

ROE

24.76%

P/VP

7.63

ABBV - AbbVie

$263.93 22,42% (12 M)

P/L

73.99

2.59%

ROE

-106.44%

P/VP

-78.76

MRK - Merck & Co.

$146.11 85,19% (12 M)

P/L

113.21

2.31%

ROE

7.55%

P/VP

8.55

AZN - AstraZeneca

$166.35 9,17% (12 M)

P/L

19.88

1.94%

ROE

25.77%

P/VP

5.12

PFE - Pfizer

$27.49 22,43% (12 M)

P/L

35.85

6.26%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of Y-mAbs Therapeutics (YMAB) today?

A cotação de Y-mAbs Therapeutics (YMAB) hoje está em US$ 0.00, com uma variação de 0% em relação ao último ano. A cotação de Y-mAbs Therapeutics (YMAB) iniciou o ano negociando na casa dos US$ 0.00 e hoje está em US$ 0.00. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Y-mAbs Therapeutics (YMAB) e dados de ações do Ibovespa e mercados internacionais.

Quando Y-mAbs Therapeutics (YMAB) paga dividendos?

Y-mAbs Therapeutics (YMAB) não distribuiu dividendos no último ano.

Is Y-mAbs Therapeutics (YMAB) a good investment?

Atualmente, Y-mAbs Therapeutics (YMAB) está cotada a US$ 0.00, com um P/L de -20.98, representando um desvio de -1,099% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 0 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Y-mAbs Therapeutics (YMAB) stock?

Investir em ações de Y-mAbs Therapeutics (YMAB) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Y-mAbs Therapeutics (YMAB) yield today?

A rentabilidade de Y-mAbs Therapeutics (YMAB) foi de 0.00% no último mês, 0.00% no último ano e 0.00% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Y-mAbs Therapeutics (YMAB) hoje, o investimento total seria de US$ 0.00, com base na cotação atual de US$ 0.00.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 0.00
Em 5 anos: US$ 0.00
Em 10 anos: US$ 0.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

YMAB

Y-mAbs Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment YMAB

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING YMAB WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Y-mAbs Therapeutics

Y-mAbs Therapeutics Inc.

United States

11 years

2018

104

PROFIT X PRICE YMAB

Financial Results YMAB

YMAB cash flow

Asset, Revenue and Profit Growth - YMAB

YMAB balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions